BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
about
Regulation of Bim in Health and DiseaseRBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified.CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.Therapeutic inhibition of BCL-2 and related family members.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
P2860
Q26781203-19A7FA1F-2398-434A-8A55-D672A5C74F42Q35967910-87513078-B201-489A-B2EC-D85677C68332Q36247617-6D2D96A3-A21F-47BA-B3AD-B70FB6911B95Q36426910-EE105BA0-83AD-4143-80A4-2216015D2021Q37014107-FC00FD3E-0A7F-44D4-BA3F-847236DA9B03Q37376388-EE28A2EF-8142-4CF4-A453-619CFF88C9C3Q37694737-F8F5C9DE-DE50-418B-8E2B-0ECEEBA9FA62Q38704051-B13B54CF-D350-40D7-9329-2E83EF571E5CQ38999126-C9E74405-2FFA-4920-B52E-9A1A2A86BB76Q39120136-9465457B-8CCC-445D-89DB-EF253EC8AE24Q41009977-E4B75C1E-E9EE-46CB-8464-5BFF5F04F4ACQ41840259-C1C3D7AE-88A4-4A00-8612-B2621B7E370FQ46370948-08E49949-33BD-4A1C-9DD6-284B2981D169Q51160337-9DAAE00A-AC36-4FB7-9C07-0B468BBE24EEQ51842580-6C7B1701-0957-47EC-9086-395AA23765AC
P2860
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
BH3 Inhibitor Sensitivity and ...... Lymphoblastic Leukemia Cells.
@ast
BH3 Inhibitor Sensitivity and ...... Lymphoblastic Leukemia Cells.
@en
type
label
BH3 Inhibitor Sensitivity and ...... Lymphoblastic Leukemia Cells.
@ast
BH3 Inhibitor Sensitivity and ...... Lymphoblastic Leukemia Cells.
@en
prefLabel
BH3 Inhibitor Sensitivity and ...... Lymphoblastic Leukemia Cells.
@ast
BH3 Inhibitor Sensitivity and ...... Lymphoblastic Leukemia Cells.
@en
P2093
P2860
P1433
P1476
BH3 Inhibitor Sensitivity and ...... e Lymphoblastic Leukemia Cells
@en
P2093
Anisha Kothari
Henriette M Goselink
Inge Jedema
J H Frederik Falkenburg
Joshua M Eichhorn
Nandini Sakurikar
Robert L Saylors
Sarah E Alford
Timothy C Chambers
P2860
P304
P356
10.1158/0008-5472.CAN-14-1849
P407
P577
2015-02-03T00:00:00Z